Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT0LF7H)

• DTT Name: Fibroblast growth factor receptor (FGFR) DTT Info
• Gene Name: FGFR

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[1]
Futibatinib	DMWM4D0	Intrahepatic cholangiocarcinoma	2C12.10	Approved	[2]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[3]
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[4]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[3]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[3]
BAY1163877	DMCSGJ2	Bladder cancer	2C94	Phase 2	[5]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
ICP-192	DM524GR	Bladder cancer	2C94	Phase 2	[7]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

4 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ARO 087	DMNAJQY	Solid tumour/cancer	2A00-2F9Z	Investigative	[8]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[4]
SU4984	DMWVN8R	Discovery agent	N.A.	Investigative	[4]
SU5403	DMV1408	Discovery agent	N.A.	Investigative	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [2] TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
• [5] Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.
• [6] The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
• [7] Clinical pipeline report, company report or official report of InnoCare Pharma.
• [8] J Clin Oncol 33, 2015 (suppl; abstr 2545).